Daily urinary neopterin excretion as an immunological marker of disease, activity in multiple sclerosis

Brain

Volumn 120, Issue 1, 1997, Pages 1-13

  Giovannoni, Gavin ^a   Lai, M ^a   Kidd, D ^a   Thorpe, J W ^a   Miller, D H ^a   Thompson, A J ^a   Keir, G ^a   Feldmann, M ^b   Thompson, E J ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Interferon gamma; Multiple sclerosis; Neopterin

Indexed keywords

CREATININE; GAMMA INTERFERON; NEOPTERIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE URINE LEVEL; DISEASE ACTIVITY; DISEASE MARKER; FEMALE; HUMAN; INFECTION; MACROPHAGE; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; RELAPSE; TIME; UPPER RESPIRATORY TRACT INFECTION; URINARY EXCRETION;

ADULT; BIOLOGICAL MARKERS; BIOPTERIN; CREATININE; FEMALE; HUMANS; INFECTION; INFLAMMATION; INTERFERON TYPE II; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NEOPTERIN; RECURRENCE;

EID: 0031049813     PISSN: 00068950     EISSN: None     Source Type: Journal    
DOI: 10.1093/brain/120.1.1     Document Type: Article

References (44)

1. Allen IV. Pathology of multiple sclerosis. In: Matthews WB. Compston A, Allen IV. Martyn CN. editors. McAlpine's multiple sclerosis. 2nd ed. Edinburgh: Churchill Livingstone. 1991: 341-8.
2. Andersen O, Lygner P-E, Berstrom T, Andersson M, Vahlne A. Viral infections trigger multiple sclerosis relapses: a prospective seroepidemiological study. J Neurol 1993; 240: 417-22.
3. Arnold DL, Riess GT, Matthews PM, Francis GS, Collins DL, Wolfson C, et al. Use of proton magnetic resonance spectroscopy for monitoring disease progression in multiple sclerosis. Ann Neurol 1994; 36: 76-82.
4. Auzéby A, Bogdan A, Krosi Z, Touitou Y. Time-dependence of urinary neopterin, a marker of cellular immune activity. Clin Chem 1988; 34: 1866-7.
5. Beck J, Rondot P, Catinot L, Falcoff E, Kirchner H, Wietzerbin J. Increased production of interferon gamma and tumor necrosis factor precedes clinical manifestation in multiple sclerosis: do cytokines trigger off exacerbations? Acta Neurol Scand 1988; 78: 318-23.
6. Cannella B, Raine CS. The adhesion molecule and cytokine profile of multiple sclerosis lesions [see comments. Ann Neurol 1995; 37: 424-35. Comment in: Ann Neurol 1995; 37: 419-21.
7. Cannella B, Raine CS. The adhesion molecule and cytokine profile of multiple sclerosis lesions [see comments. Ann Neurol 1995; 37: 424-35. Comment in: Ann Neurol 1995; 37: 419-21.
8. Capra R, Marciano N, Vignolo LA, Chiesa A, Gasparotti R. Gadolinium-pentetic acid magnetic resonance imaging in patients with relapsing remitting multiple sclerosis [see comments]. Arch Neurol 1992; 49: 687-9. Comment in: Arch Neurol 1992; 49: 685-6, Comment in: Arch Neurol 1993; 50: 569-71.
9. Capra R, Marciano N, Vignolo LA, Chiesa A, Gasparotti R. Gadolinium-pentetic acid magnetic resonance imaging in patients with relapsing remitting multiple sclerosis [see comments]. Arch Neurol 1992; 49: 687-9. Comment in: Arch Neurol 1992; 49: 685-6, Comment in: Arch Neurol 1993; 50: 569-71.
10. Capra R, Marciano N, Vignolo LA, Chiesa A, Gasparotti R. Gadolinium-pentetic acid magnetic resonance imaging in patients with relapsing remitting multiple sclerosis [see comments]. Arch Neurol 1992; 49: 687-9. Comment in: Arch Neurol 1992; 49: 685-6, Comment in: Arch Neurol 1993; 50: 569-71.
11. Chiang J, Gloff CA, Yoshizawa CN, Williams GJ. Pharmacokinetics of recombinant human interferon-beta(ser) in healthy volunteers and its effect on serum neopterin. Pharm Res 1993; 10: 567-72.
12. Compston DAS. Genetic susceptibility to multiple sclerosis. In: Matthews WB, Compston A, Allen IV, Martyn CN, editors. McAlpine's multiple sclerosis. 2nd ed. Edinburgh: Churchill Livingstone, 1991: 301-19.
13. Confavreux C, Aimard G, Devic M. Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients. Brain 1980; 103: 281-300.
14. Davie CA, Miller DH, Barker GJ, Webb S, Thompson AJ, McDonald WI. Use of magnetic resonance spectroscopy to investigate disability in multiple sclerosis [abstract]. Ann Neurol 1994; 36: 301.
15. Fierz W, Dommasch D, Niederwiesser A, Neopterin in cerebrospinal fluid as a parameter of local cellular immune reactions in the central nervous system. In: Lowenthal A, Raus J, editors. Cellular and humoral immunological components of cerebrospinal fluid in multiple sclerosis. New York: Plenum Press, 1987: 369-79.
16. Filippi M, Barker GJ, Horsfield MA, Sacares PR, MacManus DG, Thompson AJ, et al. Benign and secondary progressive multiple sclerosis: a preliminary quantitative MRI study. J Neurol 1994; 241: 246-51.
17. Fredrikson S, Link H, Eneroth P. CSF neopterin as marker of disease activity in multiple sclerosis. Acta Neurol Scand 1987; 75: 352-5.
18. Fuchs D, Weiss G, Reibnegger G, Wachter H. The role of neopterin as a monitor of cellular immune activation in transplantation, inflammatory, infectious, and malignant diseases. [Review]. Crit Rev Clin Lab Sci 1992; 29: 307-41.
19. Huber C, Batchelor JR, Fuchs D, Hausen A, Lang A, Niederwieser D, et al. Immune response-associated production of neopterin. Release from macrophages primarily under control of interferon-gamma. J Exp Med 1984; 160: 310-6.
20. Kidd D, Thorpe JW, Kendall BE, Barker GJ, Miller DH, McDonald WI, et al. MRI dynamics of brain and spinal cord in progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 1996; 60: 15-9.
21. Koopmans RA, Li DKB, Oger JJF, Kastrukoff LF, Jardine C, Costley L, et al. Chronic progressive multiple sclerosis: serial magnetic resonance brain imaging over six months. Ann Neurol 1989; 26: 248-56.
22. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444-52.
23. Kwon NY, Nathan CF, Stuehr DJ. Reduced biopterin as a cofactor in the generation of nitrogen oxides by murine macrophages. J Biol Chem 1989; 264: 20496-501.
24. Lassmann H, Suchanek G, Ozawa K. Histopathology and the blood-cerebrospinal fluid barrier in multiple sclerosis. Ann Neurol 1994; 36 Suppl: S42-6.
25. Liberati AM, Garofani P, De Angelis V, Di Clemente F, Horisberger M, Cecchini M, et al. Double-blind randomized phase I study on the clinical tolerance and pharmacodynamics of natural and recombinant interferon-β given intravenously. J Interferon Res 1994; 14: 61-9.
26. Miller DH, Rudge P, Johnson G, Kendall BE, MacManus DG, Moseley IF, et al. Serial gadolinium enhanced magnetic resonance imaging in multiple sclerosis. Brain 1988; 111: 927-39.
27. Miller DH, Thompson AJ, Morrissey SP, MacManus DG, Moore SG, Kendall BE, et al. High-dose steroids in acute relapses of multiple sclerosis: MRI evidence for a possible mechanism of therapeutic effect. J Neurol Neurosurg Psychiatry 1992; 55: 450-3.
28. Niederwieser A, Staudenmann W, Wetzel E. Automatic HPLC of pterins with or without column switching. In: Wachter H, Curtius HC, Pfleider W, editors. Biochemical and clinical aspects of pteridines, Vol. 1. Berlin: Walter de Gruyter, 1982: 81-102.
29. Ott M, Demisch L, Engelhardt W, Fischer P-A. Interleukin-2, soluble interleukin-2-receptor, neopterin, L-tryptophan and β2-microglobulin levels in CSF and serum of patients with relapsing-remitting or chronic-progressive multiple sclerosis. J Neurol 1993; 241: 108-14.
30. Panitch HS. Influence of infection on exacerbations of multiple sclerosis. Ann Neurol 1994; 36 Suppl: S25-8.
31. Panitch HS, Hirsch RL, Haley AS, Johnson KP. Exacerbations of multiple sclerosis in patients treated with gamma interferon. Lancet 1987; 1: 893-5.
32. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983; 13: 227-31.
33. Revesz T, Kidd D, Thompson AJ, Barnard RO, McDonald WI. A comparison of the pathology of primary and secondary progressive multiple sclerosis. Brain 1994; 117: 759-65.
34. Shaw CE, Dunbar PR, Macaulay HA, Neale TJ. Measurement of immune markers in the serum and cerebrospinal fluid of multiple sclerosis patients during clinical remission. J Neurol 1995; 242: 53-8.
35. Sibley WA, Bamford CR, Clark K. Clinical viral infections and multiple sclerosis. Lancet 1985; 1: 1313-5.
36. Tayeh MA, Marletta MA. Macrophage oxidation of L-arginine to nitric oxide, nitrite, and nitrate. Tetrahydrobiopterin is required as a cofactor. J Biol Chem 1989; 264: 19654-8.
37. Thompson AJ, Kermode AG, Wicks D, MacManus DG, Kendall BE, Kinglsey DP, et al. Major differences in the dynamics of primary and secondary progressive multiple sclerosis. Ann Neurol 1991; 29: 53-62.
38. Thompson AJ, Miller D, Youl B, MacManus D, Moore S, Kinglsey D, et al. Serial gadolinium-enhanced MRI in relapsing/remitting multiple sclerosis of varying disease duration. Neurology 1992; 42: 60-3.
39. Traugott U, Lebon P. Multiple sclerosis: involvement of interferons in lesion pathogenesis. Ann Neurol 1988; 24: 243-51.
40. Verdier-Taillefer M-H, Roullet E, Cesaro P, Alperovitch A. Validation of self-reported neurological disability in multiple sclerosis [see comments]. Int J Epidemiol 1994; 23: 148-54. Comment in: Int J Epidemiol 1995; 24: 466.
41. Verdier-Taillefer M-H, Roullet E, Cesaro P, Alperovitch A. Validation of self-reported neurological disability in multiple sclerosis [see comments]. Int J Epidemiol 1994; 23: 148-54. Comment in: Int J Epidemiol 1995; 24: 466.
42. Wachter H, Fuchs D, Hausen A, Reibnegger G, Weiss G, Werner ER, editors. Neopterin: biochemistry - methods - clinical application. Berlin: Walter de Gruyter, 1992.
43. Werner-Felmayer G, Werner ERR, Fuchs D, Hausen A, Reibnegger G, Wachter H. Neopterin formation and tryptophan degradation by a human myelomonocytic ceil line (THP-1) upon cytokine treatment. Cancer Res 1990; 50: 2863-7.
44. Willoughby EW, Grochowski E, Li DKB, Oger J, Kastrukoff LF, Paty DW. Serial magnetic resonance scanning in multiple sclerosis: a second prospective study in relapsing patients. Ann Neurol 1989; 25: 43-9.